WTC
NTLA icon

WhitTier Trust Company’s Intellia Therapeutics NTLA Stock Holding History

WhitTier Trust Company’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.92K Hold
225
– – ﹤0.01% 1208
2026
Q1 		$2.99K Hold
225
– – ﹤0.01% 1217
2025
Q4 		$2.19K Hold
225
– – ﹤0.01% 1165
2025
Q3 		$4.49K Buy
+225
New +$2.77K ﹤0.01% 1087

Other funds holding NTLA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
CIC
Canal Insurance Company Greenville, South Carolina $456M AUM 40.11% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

WhitTier Trust Company's NTLA Position: Q2 2026 in Review

WhitTier Trust Company held its Intellia Therapeutics (NTLA) position steady in Q2 2026 at 225 shares worth $3.92K. The position accounts for ﹤0.01% of the portfolio, ranked #1208.

WhitTier Trust Company first reported a position in NTLA in Q3 2025 and has held it in 4 quarters since. The position peaked at $4.49K in Q3 2025. 130 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • WhitTier Trust Company held 225 shares of Intellia Therapeutics worth $3.92K as of Q2 2026.
  • WhitTier Trust Company left its Intellia Therapeutics share count unchanged in Q2 2026.
  • Intellia Therapeutics made up ﹤0.01% of WhitTier Trust Company's portfolio in Q2 2026, its #1208 holding.
  • WhitTier Trust Company first reported a position in Intellia Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • WhitTier Trust Company's Intellia Therapeutics position peaked at $4.49K in Q3 2025.
  • 130 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on WhitTier Trust Company's 13F filing for Q2 2026, filed 28 Jul 2026.